- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.06. | Galecto, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.05. | Galecto GAAP EPS of -$1.92 | 2 | Seeking Alpha | ||
| 08.05. | Galecto, Inc. Q1 Loss Declines | - | RTTNews | ||
| 08.05. | Galecto, Inc.: Galecto Reports First Quarter 2025 Operating and Financial Results | 100 | GlobeNewswire (Europe) | BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced... ► Artikel lesen | |
| GALECTO Aktie jetzt für 0€ handeln | |||||
| 08.05. | Galecto, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 19.03. | Galecto GAAP EPS of -$18.53 misses by $2.62 | 4 | Seeking Alpha | ||
| 19.03. | Galecto, Inc.: Galecto Reports Full-Year 2024 Financial Results | 215 | GlobeNewswire (Europe) | Completed strategic review to focus on oncology and liver diseases with the acquisition of global rights to GB3226 (formerly BRM-1420), a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets... ► Artikel lesen | |
| 19.03. | Galecto, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 8 | SEC Filings | ||
| 19.03. | Galecto, Inc. - 10-K, Annual Report | 4 | SEC Filings | ||
| 01.11.24 | Galecto, Inc.: Galecto Reports Third Quarter 2024 Financial Results | 210 | GlobeNewswire (Europe) | - Completed strategic review to focus on oncology and severe liver diseases - Announced acquisition of global rights to BRM-1420, a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets... ► Artikel lesen | |
| 28.08.24 | Galecto, Inc.: Galecto Announces Reverse Stock Split | 213 | GlobeNewswire (Europe) | BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 7,138 | -0,81 % | Deutz Aktie: Vorsicht, es wird kritisch! - Dazu: Allianz, Evotec, Kontron, Mutares, TUI - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,120 | -1,64 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
| MAINZ BIOMED | 2,775 | -100,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von Bauchspeicheldrüsenkrebs | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von... ► Artikel lesen | |
| VIKING THERAPEUTICS | 22,700 | +0,13 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735 | VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes
SAN DIEGO, June 25, 2025 /PRNewswire/ -- Viking... ► Artikel lesen | |
| TREVENA | 0,153 | 0,00 % | Delisting of Securities of Patria Latin American Opportunity Acquisition Corp.; Trevena, Inc.; Seelos Therapeutics, Inc.; DP Cap Acquisition Corp I; Chain Bridge I; Qomolangma Acquisition Corp.; Gaucho Group Holdings, Inc. ... | NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the Class A Ordinary Shares, unit, and warrant of Patria Latin American Opportunity Acquisition... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 7,800 | -1,76 % | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenCA39261L2049 Green Battery Minerals Inc. 23.06.2025 CA3194101067 First Canadian Grahite Inc. 24.06.2025 Tausch 1:1US15117F8077 Cellectar... ► Artikel lesen | |
| GALAPAGOS NV | 24,160 | +1,00 % | Galapagos NV: Galapagos Appoints Aaron Cox as Chief Financial Officer | Former Horizon CFO joins Galapagos with deep expertise in international corporate finance, M&A, business development and strategic leadership
Mechelen, Belgium; June 23, 2025, 07:30 CET; regulated... ► Artikel lesen | |
| CENTOGENE | 0,149 | +49,00 % | Research and Markets: Europe Hereditary Genetic Testing Market Research 2024-2033, Competitive Analysis of Centogene, Eurofins Scientific, and F. Hoffmann-La Roche - ResearchAndMarkets.com | The "Europe Hereditary Genetic Testing Market: Focus on Genetic Testing Type and Country Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 2,813 | -100,00 % | XFRA FA20,0RA0,4070: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILFORWARD AIR CORP.... ► Artikel lesen | |
| AC IMMUNE | 1,738 | +0,46 % | AC Immune SA: AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update | AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update Continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative diseasesPositive... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 2,076 | +7,79 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA (pembrolizumab) in Patients with Metastatic Melanoma | SOUTH SAN FRANCISCO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the... ► Artikel lesen | |
| CYTOKINETICS | 28,400 | 0,00 % | Cytokinetics, Incorporated: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 15, 2025 it granted stock options to purchase an aggregate of... ► Artikel lesen | |
| SPERO THERAPEUTICS | 2,500 | -0,79 % | Alleviating the Pain of CRPS Gave Heather Her Life Back: The Spero Clinic's Role in the Recovery | Is it possible that a simple sound can hurt you? That the sound of a bird singing in the yard can make you scream out in pain? That's the reality of having CRPS. Here's how the Spero Clinic helped Heather... ► Artikel lesen | |
| PERSONALIS | 5,450 | -3,28 % | Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue | FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and... ► Artikel lesen | |
| PULMATRIX | 5,810 | +1,57 % | Pulmatrix Inc.: Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets | Registration statement for proposed Cullgen merger declared effective by the SEC
Proposed merger anticipated to close in June
As part of proposed merger, Pulmatrix... ► Artikel lesen |
Das Unternehmen GALECTO INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 3,380 Euro und damit -3,43 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GALECTO INC finden Sie auf Wallstreet Online.